The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Inclusion Criteria:
OR presence of 2 low risk factors: Age > 35, post-partum hemorrhage > 1000 ml, Cesarean section, Hysterectomy, BMI > 30, Multiparity- Third birth or more, Active Smoking, Obstetric complications in current pregnancy (including preeclampsia, preterm birth before 37 weeks, active infection including chorioamnionitis, prolonged labor over 24 hours), Twin birth, Immobility, Large varicose veins, Stillbirth
Exclusion Criteria:
n_gridish@rambam.health.gov.il+972503027855
Apixaban. 2.5 mg administered orally twice a day
Enoxaparin. 40 mg (or 60 mg for weight \> 91 kg) administered subcutaneously once a day
Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
Low Molecular Weight hEparin vs. Aspirin Post-partum
Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy